|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Oxford,GB
|
|
T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK.
We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune & inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies.
Our goals:
- Develop next generation TCR therapies for treatment of cancer and autoimmune disease
- Innovate to make TCR therapies widely available to patients
About T-Cypher
- Founded in 2021 based on exclusive technology licenses from University of Oxford, and with Oxford Science Enterprises as the major shareholder
- Proprietary disease target and TCR discovery platform
- Expanding TCR-bank against novel, differentiated targets
- Differentiated approach to multiplexing TCRs in therapeutic T-cells
- Diverse team with experienced leadership from prominent companies covering cell therapy, gene engineering, immune oncology, autoimmune disease and computational biology
|
T-Cypher Bio Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used T-Cypher Bio email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact T-Cypher Bio customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.